An Investigational Study of Immunotherapy Combinations in ParticipantsWith Solid Cancers That Are Advanced or Have Spread
- Conditions
- Advanced Malignant TumorsMedDRA version: 21.0Level: LLTClassification code: 10048683Term: Advanced cancer Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-508207-21-00
- Lead Sponsor
- Bristol Myers Squibb International Corporation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 325
Histologic or cytologic confirmation of an incurable solid malignancy that is advanced (metastatic and/or unresectable), with measurable disease per RECIST v1.1, -Available tumor tissue for biomarker analysis, - Eastern Cooperative Oncology Group Performance Status (ECOG) status of 0 or 1
- Participants with known or suspected uncontrolled CNS metastases or with the CNS as the only site of active disease, - Participants with a history of interstitial lung disease (ILD) /pneumonitis, - Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment assignment (ie, participants with a history of prior malignancy are eligible if treatment was completed at least 2 years before treatment assignment and the participant has no evidence of disease). Participants with history of prior early stage basal/squamous cell skin cancer or noninvasive or in situ cancers that have undergone definitive treatment at any time are also eligible
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method